Flexion Therapeutics

Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa. Dr. Muzikant will provide a review of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate in clinical development for the treatment of osteoarthritis (OA).

Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa

BURLINGTON, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Tuesday, September 15, 2020.  

Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference

BURLINGTON, Mass., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA).

Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial

BURLINGTON, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:40 a.m. ET on Wednesday, September 9, 2020.

Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

BURLINGTON, Mass., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors.

Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates

BURLINGTON, Mass., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2020.

Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights

A Relative Strength Rating upgrade for Flexion Therapeutics shows improving technical performance. Will it continue?

Stocks With Rising Relative Strength: Flexion Therapeutics

BURLINGTON, Mass., July  30, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020.

Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020

Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know

FLXN stock has been falling because the company is not in the race for a Covid-19 vaccine. But as that field narrows, FLX is worth a look.

OK Boomer, Flexion Stock Is Made For You

Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock?

BURLINGTON, Mass., July  14, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA net sales of $15.4 million for the quarter ended June 30, 2020. Demand for ZILRETTA increased month-over-month throughout the second quarter with purchases by healthcare providers reaching 4,863 units, 13,547 units and 18,287 units in April, May and June, respectively. The total ZILRETTA purchases by healthcare providers in the second quarter (approximately 36,700 units) was in line with the first quarter (36,540 units). In addition, the Company also announced plans to recommence ZILRETTA manufacturing in the fourth quarter to help ensure adequate and uninterrupted supply to meet future demand.

Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales

Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock?

BURLINGTON, Mass., June  16, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference. The virtual fireside chat is scheduled to begin at 9:30 a.m. ET on Tuesday, June 23, 2020.

Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Flexion (FLXN) Soars: Stock Adds 6.6% in Session

Planning For A Rebound In Flexion Therapeutics

The company priced a share offering, diluting existing shareholders.

Why Flexion Therapeutics Is Tumbling 10% Today

BURLINGTON, Mass., May  21, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be approximately $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about May 26, 2020, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 1,384,615 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., May  20, 2020  (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Flexion. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call Transcript

News for Flexion Therapeutics Stock (FLXN)